Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Bhansali RS, Rammohan M, Lee P, Laurent AP, Wen Q, Suraneni P, Yip BH, Tsai YC, Jenni S, Bornhauser B, Siret A, Fruit C, Pacheco-Benichou A, Harris E, Besson T, Thompson BJ, Goo YA, Hijiya N, Vilenchik M, Izraeli S, Bourquin JP, Malinge S, Crispino JD. Bhansali RS, et al. Among authors: jenni s. J Clin Invest. 2021 Jan 4;131(1):e135937. doi: 10.1172/JCI135937. J Clin Invest. 2021. PMID: 33393494 Free PMC article.
Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia.
Laurent AP, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S, Tsai YC, Roos-Weil D, Aid Z, Prade N, Lagarde S, Plassard D, Pierron G, Daudigeos E, Lecluse Y, Droin N, Bornhauser BC, Cheung LC, Crispino JD, Gaudry M, Bernard OA, Macintyre E, Barin Bonnigal C, Kotecha RS, Geoerger B, Ballerini P, Bourquin JP, Delabesse E, Mercher T, Malinge S. Laurent AP, et al. Among authors: jenni s. Clin Cancer Res. 2020 Jul 1;26(13):3307-3318. doi: 10.1158/1078-0432.CCR-19-3519. Epub 2020 Mar 27. Clin Cancer Res. 2020. PMID: 32220889 Free PMC article.
BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.
Butler M, van Ingen Schenau DS, Yu J, Jenni S, Dobay MP, Hagelaar R, Vervoort BMT, Tee TM, Hoff FW, Meijerink JP, Kornblau SM, Bornhauser B, Bourquin JP, Kuiper RP, van der Meer LT, van Leeuwen FN. Butler M, et al. Among authors: jenni s. Blood. 2021 Dec 9;138(23):2383-2395. doi: 10.1182/blood.2021011787. Blood. 2021. PMID: 34280258 Free PMC article. Clinical Trial.
Repurposing anthelmintic agents to eradicate resistant leukemia.
Mezzatesta C, Abduli L, Guinot A, Eckert C, Schewe D, Zaliova M, Vinti L, Marovca B, Tsai YC, Jenni S, Aguade-Gorgorio J, von Stackelberg A, Schrappe M, Locatelli F, Stanulla M, Cario G, Bourquin JP, Bornhauser BC. Mezzatesta C, et al. Among authors: jenni s. Blood Cancer J. 2020 Jun 26;10(6):72. doi: 10.1038/s41408-020-0339-9. Blood Cancer J. 2020. PMID: 32591499 Free PMC article.
TNFR2 is required for RIP1-dependent cell death in human leukemia.
Aguadé-Gorgorió J, McComb S, Eckert C, Guinot A, Marovca B, Mezzatesta C, Jenni S, Abduli L, Schrappe M, Dobay MP, Stanulla M, von Stackelberg A, Cario G, Bourquin JP, Bornhauser BC. Aguadé-Gorgorió J, et al. Among authors: jenni s. Blood Adv. 2020 Oct 13;4(19):4823-4833. doi: 10.1182/bloodadvances.2019000796. Blood Adv. 2020. PMID: 33027529 Free PMC article.
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P. De Smedt R, et al. Among authors: jenni s. Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076176 Free PMC article. No abstract available.
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.
Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, Scheffold A, Villalobos-Ortiz M, Boldrin E, Zinngrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, Kestler HA, Bourquin JP, Stilgenbauer S, Letai A, Debatin KM, Meyer LH. Seyfried F, et al. Among authors: jenni s. Cell Death Dis. 2019 Jul 29;10(8):571. doi: 10.1038/s41419-019-1801-0. Cell Death Dis. 2019. PMID: 31358732 Free PMC article.
The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability.
Huang Y, Mouttet B, Warnatz HJ, Risch T, Rietmann F, Frommelt F, Ngo QA, Dobay MP, Marovca B, Jenni S, Tsai YC, Matzk S, Amstislavskiy V, Schrappe M, Stanulla M, Gstaiger M, Bornhauser B, Yaspo ML, Bourquin JP. Huang Y, et al. Among authors: jenni s. Cancer Cell. 2019 Dec 9;36(6):630-644.e9. doi: 10.1016/j.ccell.2019.10.004. Epub 2019 Nov 14. Cancer Cell. 2019. PMID: 31735627 Free article.
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, Balasubramanian GP, Bandapalli OR, Higi S, Eugster S, Voegeli P, Delorenzi M, Cario G, Loh ML, Schrappe M, Stanulla M, Kulozik AE, Muckenthaler MU, Saha V, Irving JA, Meisel R, Radimerski T, Von Stackelberg A, Eckert C, Tyner JW, Horvath P, Bornhauser BC, Bourquin JP. Frismantas V, et al. Among authors: jenni s. Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25. Blood. 2017. PMID: 28122742 Free PMC article.
105 results